Trial Profile
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Bremelanotide (Primary)
- Indications Decreased libido; Female sexual dysfunction
- Focus Therapeutic Use
- Acronyms RECONNECT
- Sponsors Palatin Technologies
- 01 Mar 2022 Results of this study and the extension study assessing pre-specified and sub-group analysis assessing efficacy of bremelanotide were published in the Journal of Women's Health.
- 16 Oct 2019 According to a Palatin Technologies media release, data from RECONNECT trials will be presented by Sheryl Kingsberg at the 13th European Society of Gynecology Conference 2019. The conference and the data presentations are jointly sponsored by Palatin and AMAG Pharmaceuticals, Inc.
- 11 Oct 2019 Results published in the AMAG Pharmaceuticals Media Release